Targeting polyamine metabolism: a viable therapeutic/preventative solution for cancer?

Bibliography

• WALLACE HM, FRASER AV, HUGHES A: A perspective of polyamine metabolism. Biochem. J. (2003) 376:1-14.
   PubMed Web of Science ®Google Scholar
• KAY JE, LINDSAY VJ: Polyamine synthesis during lymphocyte activation. Induction of ornithine decarboxylase and S-adenosyl methionine decarboxylase. Exp. Cell Res. (1973) 77:428-436.
   PubMed Web of Science ®Google Scholar
• KNUTSON JC, MORRIS DR: Cellular polyamine depletion reduces DNA synthesis in isolated lymphocyte nuclei. Biochem. Biophys. Acta (1978) 520:291-302.
   PubMed Web of Science ®Google Scholar
• WALLACE HM, KEIR HM: Uptake and excretion of polyamines from baby hamster kidney cells (BHK-21/C13): the effect of serum on confluent cell cultures. Biochim. Biophys. Acta (1981) 676:25-30.
   PubMed Web of Science ®Google Scholar
• KINGSNORTH AN, LUMSDEN AB, WALLACE HM: Polyamines in colorectal cancer. Br. J. Surg. (1984) 71:791-794.
   PubMed Web of Science ®Google Scholar
• KINGSNORTH AN, WALLACE HM, BUNDRED NJ et al.: Polyamines in breast cancer. Br. J. Surg. (1984) 71:352-356.
   PubMed Web of Science ®Google Scholar
• TABOR CW, TABOR H, HAFNER EW: Eschericia coli mutants completely deficient in adenosylmethinoine decarboxylase and in spermidine biosynthesis. J. Biol. Chem. (1978) 253:2671-2576.
   Google Scholar
• MARTON LJ, PEGG AE: Polyamines as targets for therapeutic intervention. Annu. Rev. Pharmacol. Toxicol. (1995) 35:55-91.
   PubMed Web of Science ®Google Scholar
• JANNE J, ALHONEN L, PIETILA M et al.: Genetic approaches to the cellular functions of polyamines in mammals. Eur. J. Biochem. (2004) 271:877-894.
   PubMedGoogle Scholar
• HUANG Y, PLEDGIE A, CASERO RA et al.: Molecular mechanisms of polyamine analogs in cancer cells. Anticancer drugs (2005) 16:229-241.
   PubMed Web of Science ®Google Scholar
• WANG Y, DEVEREUX W, WOSTER PM et al.: Cloning and characterisation of a human polyamine oxidase that is inducible by polyamine analogue exposure. Cancer Res. (2001) 61:5370-5373.
   PubMed Web of Science ®Google Scholar
• WALLACE HM, FRASER AV: Polyamine analogues as anticancer drugs. Biochem. Soc. Trans. (2003) 31:393-396.
   PubMed Web of Science ®Google Scholar
• METCALF BW, BEY P, DANZIN C et al.: Catalytic irreversible inhibition of mammalian decarboxylase (EC 4.1.1.17) by substrate and product analogues. J. Am. Chem. Soc. (1978) 100:2551-2553.
   Web of Science ®Google Scholar
• KUBOTA S, OHSAWA N, TAKAKU F: Effects of Dl-a-difluoromethylornithine on the growth and metastases of B16 melanoma in vivo. Int. J. Cancer (1987) 39:244-247.
   PubMed Web of Science ®Google Scholar
• REGENASS U, CARAVATTI G, METT H et al.: New S-adenosylmethionine decarboxylase inhibitors with potent antitumour activity. Cancer Res. (1992) 52:4712-4718.
   PubMed Web of Science ®Google Scholar
• BOLKENIUS FN, BEY P, SEILER N: Specific inhibition of polyamine oxidase in vivo is a method for the elucidation of its physiological role. Biochem. Biophys. Acta (1985) 838:69-76.
   PubMedGoogle Scholar
• WANG Y, MURRAY-STEWART T, DEVEREUX W et al.: Properties of purified recombinant human polyamine oxidase PAOh1/SMO. Biochem. Biophys. Res. Commun. (2003) 304:605-611.
   PubMed Web of Science ®Google Scholar
• ZWELLING LA, KERRIGAN D, MARTON LJ: Effect of difluoromethylornithine, an inhibitor of polyamine biosynthesis, on the topoisomerase II-mediated DNA scission produced by 4′-(9-acridinylamino)methanesulfon-m-anisidide in L1210 murine leukaemia cells. Cancer Res. (1985) 45:1122-1126.
   PubMed Web of Science ®Google Scholar
• MANNI A, BADGER B, WECHTER R et al.: Biochemical and growth modulatory effects of the new S-adenosylmethionine decarboxylase inhibitor CGP 48664 in malignant and immortalised human breast epithelial cell sin culture. Int. J. cancer (1995) 62:485-491.
   PubMed Web of Science ®Google Scholar
• ALHONEN-HONGISTO L, SEPPANEN P, JANNE J: Intracellular putrescine and spermidine deprivation induces increased uptake of the natural polyamines and methylglyoxal bis(guanylhydrazone). Biochem. J. (1980) 192:941-945.
   PubMed Web of Science ®Google Scholar
• PORTER CW, McMANIS J, CASERO RA et al.: Relative abilities of bis(ethyl) derivatives of putrescine, spermidine and spermine to regulate polyamine biosynthesis and inhibit L1210 leukaemic growth. Cancer Res. (1987) 47:2821-2825.
   PubMed Web of Science ®Google Scholar
• McCLOSKEY DE, YANG J, WOSTER PM et al.: polyamine analogue-induction of programmed cell death in human lung tumour cells. Clin. Cancer Res. (1996) 2:441-446.
   PubMed Web of Science ®Google Scholar
• PORTER CW, GANIS B, LIBBY PR et al.: Correlations between polyamine analogue-induced increases in spermidine/spermine N1-acetyltransferase activity, polyamine pool depletion and growth inhibition in human melanoma cell lines. Cancer Res. (1991) 51:3715-3720.
   PubMed Web of Science ®Google Scholar
• CASERO RA, WOSTER PM: Terminally alkylated polyamine analogues as chemotherapeutic agents. J. Med. Chem. (2001) 44:1-26.
   PubMed Web of Science ®Google Scholar
• WOSTER PM: Polyamine structure and synthetic analogues. In: Polyamine Cell Signalling Physiology, Pharmacology and Cancer Research. Wang J-Y, Casero RA (Eds), Humana Press, New Jersey (2006):3-24.
   Google Scholar
• NAIRN LM, LINDSAY GS, WOSTER PM et al.: Cytotoxicity of novel unsymmetrically substituted inhibitors of polyamine biosynthesis in human cancer cells. J. Cell Physiol. (2000) 182:209-213.
   PubMed Web of Science ®Google Scholar
• VALASINAS A, REDDY VK, BLOKHIN AV et al.: Long-chain polyamines (oligoamines) exhibit strong cytotoxicities against human prostate cancer cells. Bioorg. Med. Chem. (2003) 11(18):4121-4131.
   PubMed Web of Science ®Google Scholar
• FRYDMAN B, PORTER CW, MAXUITENKO Y et al.: A novel polyamine analog (SL-11093) inhibits growth of human prostate tumor xenografts in nude mice. Cancer Chemother. Pharmacol. (2003) 51(6):488-492.
   PubMed Web of Science ®Google Scholar
• O'SHAUGHNESSY JA, DEMERS LM, JONES SE et al.: a-Difluoromethylornithine as treatment for metastatic breast cancer patients. Clin. Cancer Res. (1999) 5(11):3438-3444.
   PubMed Web of Science ®Google Scholar
• WONG ET, HESS KR, GLEASON MJ et al.: Outcomes and prognostic factors in recurrent glioma patients enrolled onto Phase II clinical trials. J. Clin. Oncol. (1999) 17(8):2572-2578.
   PubMed Web of Science ®Google Scholar
• NIE L, FENG W, DIAZ R et al.: Functional consequences of polyamine synthesis inhibition by L-α-difluormethylornithine (DFMO). Cellular mechanisms for DFMO-mediated ototoxicity. J. Biol. Chem. (2005) 280(15):15097-15102.
   PubMed Web of Science ®Google Scholar
• LEVIN VA, UHM JH, JAECKLE KA et al.: Phase III randomised study of postradiotherapy chemotherapy with a-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N′-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multeforme. Clin. Cancer Res. (2000) 6:3878-3884.
   PubMed Web of Science ®Google Scholar
• Vlastos A-T, WEST LA, ATKINSON EN et al.: Results of a Phase II double-blinded randonised clinical trial of difluoromethylornithine for cervical intraepithelial neoplasia grades 2 and 3. Clin. Cancer Res. (2005) 11:390-396.
   PubMed Web of Science ®Google Scholar
• MEYSKENS FL Jr, GERNER EW: Development of difluoromethylornithine (DFMO) as a chemoprevention agent. Clin. Cancer Res. (1999) 5:945-951.
   PubMed Web of Science ®Google Scholar
• MITCHELL MF, TORTOLERO-LUNA G, LEE JJ et al.: Phase I dose de-escalation trial of a-difluoromethylornithine in patients with grade 3 cervical intraepithelial neoplasia. Clin. Cancer Res. (1998) 4:303-310.
   PubMed Web of Science ®Google Scholar
• CARBONE PP, PIRSCH JD, THOMAS JP et al.: Phase I chemoprevention study of difluoromethylornithine in subjects with organ transplants. Cancer Epidemiol. Biomarkers Prev. (2001) 10:657-661.
   PubMed Web of Science ®Google Scholar
• SIMONEAU AR, GERNER EW, PHUNG M, MCLAREN CD, MEYSKENS FL Jr: α-Difluotomethylornithine and polyamine levels in the human prostate: results of a Phase IIa trial. J. Nat. Cancer Inst. (2001) 93(1):57-59.
   PubMed Web of Science ®Google Scholar
• FABIAN CJ, KIMLER BF, BRADY DA et al.: A Phase II breast cancer chemoprevention trial of oral a-difluoromehtylornithine: breast tissue, imaging, and serum and urine biomarkers. Clin. Cancer Res. (2002) 8:3105-3117.
   PubMed Web of Science ®Google Scholar
• MESSING E, KYUNGMANN K, SHARKEY F et al.: Randomized prospective trial of difluoromehtylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer. J. Urol. (2006) 176:500-504.
   PubMed Web of Science ®Google Scholar
• ALBERTS DS, DORR RT, EINSPAHR JG et al.: Chemoprevention of human actinic keratoses by topical 2-(difluoromethyl)-dl-ornithine. Cancer Epidemiol. Biomarkers. Prev. (2000) 9:1281-1286.
   PubMed Web of Science ®Google Scholar
• PEGG AE, FEITH DJ: Polyamines and neoplastic growth. Biochem. Soc. Trans. (2007) 35:295-299.
   PubMed Web of Science ®Google Scholar
• PEGG AE, WECHTER R, PAKAL R et al.: Effect of N1,N12 bis(ethyl)spermine and related compounds on growth and polyamine eacetylation, content, and excretion in human colon tumour cells. J. Biol. Chem. (1989) 264:11744-11749.
   PubMed Web of Science ®Google Scholar
• BERNACKI RJ, BERGERON RJ, PORTER CW: Antitumour activity of N1, N12-bis(ethyl)spermine homologues against human MALME 3 melanoma xenografts. Cancer Res.(1992) 52:2424-2430.
   PubMed Web of Science ®Google Scholar
• STREIFF RR, BENDER JF: Phase I study of N1,N14-diethylnorspermine (DENSPM) administered TID for 6 days in patients with advanced malignancies. Invest. N. Drugs (2001) 19:29-39.
   PubMed Web of Science ®Google Scholar
• HAHM HA, ETTINGER DS, BOWLING K et al.: Phase I Study of N1,N14-diethylnorspermine in patients with non-small cell lung cancer. Clin. Cancer Res. (2002) 8:684-690.
   PubMed Web of Science ®Google Scholar
• WILDING G, KING D, TUTSCH K et al.: Phase I trial of the polyamine analog N1,N14-diethylhomospermine (DEHSPM) in patients with advanced solid tumours. Invest. N. Drugs (2004) 22:131-138.
   PubMed Web of Science ®Google Scholar
• DAVIDSON NE, HAHM HA, MCCLOSKEY DE, WOSTER PM, CASERO RA Jr: Clinical aspects of cell death in breast cancer: the polyamine pathway as a new target for treatment. Endocr. Relat. Cancer (1999) 6:69-73.
   PubMed Web of Science ®Google Scholar
• WOLFF AC, ARMSTRONG DK, FETTING JH et al.: A Phase II study of the polyamine analog N1,N14-diethylnorspermine (DENSpm) daily for five days every 21 days in patients with previously treated metastatic breast cancer. Clin. Cancer Res. (2003) 9:5922-5928.
   PubMed Web of Science ®Google Scholar
• REGENASS U, METT H, STANEK J et al.: CGP48664 a new S-adenosylmethionine decarboxylase inhibitor with braod spectrum antiproliferative and antitumour activity. Cancer Res. (1994) 54:3210-3217.
   PubMed Web of Science ®Google Scholar
• WARRELL RP, BURCHENAL JH: Methylglyoxal bis(guanylhydrazone) (methyl-GAG). Current status and future prospects. J. Clin. Oncol. (1983) 1:52-65.
   PubMed Web of Science ®Google Scholar
• ESKENS FALM, GREIM GA, VAN ZUYLEN C et al.: Phase I and pharmacological study of weekly administration of the polyamine synthesis inhibitor SAM 486A (CGP 48 664) in patients with solid tumours. Clin. Cancer Res. (2000) 6:1736-1743.
   PubMed Web of Science ®Google Scholar
• SUI LL, ROWINSKY EK, HAMMOND LA et al.: A Phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with advanced solid malignancies. Clin. Cancer Res. (2002) 8:2157-2166.
   PubMed Web of Science ®Google Scholar
• MILLWARD MJ, JOSHUA A, KEFFORD R et al.: Multi-centre Phase II trial of the polyamine synthesis inhibitor SAM486A (CGP48664) in patients with metastatic melanoma. Invest. N. Drugs (2005) 23:253-256.
   PubMed Web of Science ®Google Scholar
• PLESS M, BELHADJ K, MENSSEN HD et al.: Clinical efficacy, tolerability, and safety of SAM486A, a novel polyamine biosynthesis inhibitor, in patients with relapsed or refractory non-Hodgkins' lymphoma: results from a Phase II multicenter study. Clin. Cancer Res. (2004) 10:1299-1305.
   PubMed Web of Science ®Google Scholar
• QUEMENER V, BLANCHARD Y, CHAMAILLARD L et al.: Polyamine deprivation: a new tool in cancer treatment. Anticancer Res. (1994) 14:443-448.
   PubMed Web of Science ®Google Scholar
• CIPOLLA B, GUILLE F, OULINOUX J-P: Polyamine-reduced diet in metastatic hormone refractory prostate cancer (HRPC) patients. Biochem. Soc. Trans. (2003) 31:384-387.
   PubMed Web of Science ®Google Scholar
• CHOI W, GERNER EW, RAMDAS L et al.: Combination of 5-fluorouracil and N1,N11-diethylnorspermine markedly activates spermidine/spermine N1-acetyltransferase expression, depletes polyamines, and synergistically induces apoptosis in colon carcinoma cells. J. Biol. Chem. (2005) 280:3295-3304.
   PubMed Web of Science ®Google Scholar